A majority of federal health advisers say a best-selling antidepressant from Eli Lilly & Co. appears effective in treating back pain, but not arthritis.
The Food and Drug Administration is considering whether to broaden approval of Cymbalta to treat chronic pain, which would expand sales of a drug already used by 15 million U.S. patients. Get the full story »
